Resolution Bioscience
Resolution Bioscience is a Kirkland, Washington-based healthcare company that developed the proprietary ctDx FIRST liquid biopsy platform for non-invasive cancer detection via circulating tumor DNA analysis, serving pharmaceutical companies with companion diagnostics for precision oncology drug development.
- Company typePrivate
- Founded2012
- HeadquartersKirkland, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Resolution Bioscience does
Resolution Bioscience is a Kirkland, Washington-based healthcare research company founded in 2012 that specialized in next-generation sequencing (NGS) technology, molecular biology, and cancer diagnostics. The company's core offering is the ctDx FIRST Liquid Biopsy Platform, a proprietary technology that analyzes circulating tumor DNA (ctDNA) to enable non-invasive cancer detection and monitoring for precision oncology applications. The platform supports pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments, addressing the industry's need for diagnostic-drug co-development and personalized medicine requirements.
The company operated with 51-100 employees under a horizontal segmentation approach, targeting pharmaceutical firms as its primary customer segment. Resolution Bioscience's revenue mechanics centered on companion diagnostic partnerships with pharma, though specific pricing, contract values, or revenue figures were not publicly disclosed. Its value proposition rested on the ctDx FIRST platform's ability to detect genomic alterations guiding treatment decisions through a non-invasive liquid biopsy workflow, with the proprietary technology cited as a strong competitive differentiator.
In September 2023, Resolution Bioscience was acquired by Exact Sciences Corporation (now rebranded under Abbott), integrating the ctDx FIRST platform into Exact Sciences' broader precision oncology portfolio alongside products such as Cologuard, Oncodetect, Oncotype DX, and Cancerguard. Post-acquisition, Resolution Bioscience operates as a wholly-owned subsidiary, with its liquid biopsy technology now distributed through Exact Sciences' established laboratory testing infrastructure, healthcare provider networks, and international footprint spanning the US, UK, Germany, France, Italy, Japan, and Poland. Mark Li serves as President and CEO.
Resolution Bioscience firmographics
Firmographics- Name
- Resolution Bioscience
- Website
- https://resolutionbio.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Resolution Bioscience is a Kirkland, Washington-based healthcare company that developed the proprietary ctDx FIRST liquid biopsy platform for non-invasive cancer detection via circulating tumor DNA analysis, serving pharmaceutical companies with companion diagnostics for precision oncology drug development.
- Ownership category
- akta.pro rank
Resolution Bioscience industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)
Keywords
Where Resolution Bioscience is headquartered
LocationHeadquarters
- HQ city
- Kirkland
- HQ country
- United States
- HQ region
- North America
Markets served
Resolution Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Resolution Bioscience product offering
Product offeringCore offering
Resolution Bioscience develops and offers the ctDx FIRST Liquid Biopsy Platform, a proprietary NGS-based diagnostic platform that analyzes circulating tumor DNA (ctDNA) for non-invasive cancer detection, monitoring, and treatment guidance. The platform serves pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments.
Product overview
Resolution Bioscience offered a focused product portfolio centered on its core ctDx FIRST liquid biopsy platform for precision oncology. The company was acquired by Exact Sciences in September 2023, integrating its liquid biopsy technology into Exact Sciences' broader cancer diagnostics offerings.
Differentiator
Problem solved
Functional benefit
Brands
- ctDx FIRST: Liquid biopsy platform for precision oncology diagnostics
Products and services
- ctDx FIRST Liquid Biopsy Platform A proprietary NGS-based liquid biopsy platform that analyzes circulating tumor DNA (ctDNA) to support non-invasive cancer detection, monitoring, and precision oncology treatment guidance. Used by pharmaceutical companies for companion diagnostic development and by clinicians to identify genomic alterations that inform targeted therapy selection.
Companies that use Resolution Bioscience
Customer profileSegments1 record
Ideal customer profiles1 record
Resolution Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Resolution Bioscience partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Resolution Bioscience competitors and assessment
Company assessmentDirect peers
- Personalis: Personalis provides NeXT Personal, a tumor-informed liquid biopsy assay for MRD and recurrence monitoring, as well as ImmunoID Next for immuno-oncology. It competes directly with Resolution Bio's ctDNA-based oncology platform.
- Foundation Medicine: Foundation Medicine's FoundationOne Liquid CDx is a directly competing FDA-approved liquid biopsy assay used for therapy selection in advanced cancer. Both companies serve biopharma CDx co-development and offer ctDNA-based therapy guidance assays.
- Tempus Labs: Tempus offers the xT and xF liquid biopsy assays for oncology genomic profiling and biopharma CDx partnerships. It directly competes in NGS-based ctDNA testing and pharma companion diagnostic services.
- Natera: Natera's Signatera tumor-informed MRD assay is a ctDNA-based liquid biopsy test used for cancer recurrence monitoring and treatment response assessment. It competes directly with Resolution Bio's MRD-adjacent liquid biopsy positioning.
- Guardant Health: Guardant Health is a leading liquid biopsy company whose Guardant360 CDx is the dominant FDA-approved ctDNA assay for comprehensive genomic profiling. It directly competes with Resolution Bio's ctDx FIRST in oncology liquid biopsy and pharma CDx partnerships.
- Caris Life Sciences: Caris offers MI Profile and Caris Assure for molecular profiling and liquid biopsy, serving oncologists and biopharma for therapy selection and CDx development — directly overlapping Resolution Bio's customer base and use cases.
Broad incumbents
- NeoGenomics: NeoGenomics is a broader oncology diagnostics services company that operates liquid biopsy offerings including the RaDaR MRD assay (acquired via Inivata). It overlaps with Resolution Bio in oncology liquid biopsy and pharma CDx services, though with a much wider test menu.
- Exact Sciences: Exact Sciences (now Abbott) is the parent company of Resolution Bioscience and operates Oncodetect, OncoExTra, and Cancerguard liquid biopsy tests. As the acquirer of Resolution Bio, it is the most important strategic incumbent shaping the subsidiary's go-forward trajectory.
Regional players
- Burning Rock Biotech: Burning Rock is a China-based liquid biopsy and NGS oncology diagnostics company offering ctDNA assays for therapy selection and MRD. It is a regional peer with comparable technology to Resolution Bio's ctDx FIRST but operates primarily in the Chinese market.
Emerging players
- Adaptive Biotechnologies: Adaptive Biotechnologies provides clonoSEQ for MRD monitoring in blood cancers and immune profiling services. While focused on hematologic malignancies, it competes for pharma CDx partnerships and oncology diagnostic spend overlapping with Resolution Bio's market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Resolution Bioscience social profiles
Digital presenceResolution Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Resolution Bioscience leadership team
Management profileNumber of profiles
Resolution Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Resolution Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Resolution Bioscience
What does Resolution Bioscience do?
Resolution Bioscience develops and offers the ctDx FIRST Liquid Biopsy Platform, a proprietary NGS-based diagnostic platform that analyzes circulating tumor DNA (ctDNA) for non-invasive cancer detection, monitoring, and treatment guidance. The platform serves pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments.
Is Resolution Bioscience a public or private company?
Resolution Bioscience is a private company. It is classified as corporate owned and is currently acquired.
When was Resolution Bioscience founded?
Resolution Bioscience was founded in 2012. It employs 51 to 100 people.
Where is Resolution Bioscience based?
Resolution Bioscience is headquartered in Kirkland, United States, in the North America region.
Who are Resolution Bioscience's main competitors?
Direct peers on record are Personalis, Foundation Medicine, Tempus Labs, Natera, Guardant Health and Caris Life Sciences. Broad incumbents are NeoGenomics and Exact Sciences. Burning Rock Biotech is listed as a regional player. Adaptive Biotechnologies is listed as an emerging player.
Does Resolution Bioscience have an API?
No public API is recorded for Resolution Bioscience.
What industry is Resolution Bioscience in?
Resolution Bioscience's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 2835.